PARP1 and glioblastoma: MG18L, a recently discovered activity of oHSV, has been shown to deteriorate RAD51 as well as sensitize GBM stem cells toward PARP inhibitors, by killing cells in an artificial lethal like manner both in vitro as well as in vivo.